C-Kit Kinase Inhibitor Compounds for Autoimmune Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds that inhibit KIT, CSF1R, and PDGFR kinases are not approved for treating autoimmune diseases or disorders involving abnormal activation of these kinases.
Innovation Solution
A compound of Formula (I) or its pharmaceutically acceptable salt, which inhibits KIT, CSF1R, and PDGFR kinases, is developed to address the abnormal activation of these kinases in various diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current compounds that inhibit KIT, CSF1R, and PDGFR kinases are used, then kinase inhibition activity is achieved, but approval for treating autoimmune diseases is not obtained
Solution Approach 1:
The patent modifies the chemical structure of existing kinase inhibitors by introducing specific substituent groups (R1, R2, R3, R4, R5, R9) and structural variations (m, n values) to optimize the compound's properties for autoimmune disease treatment, thereby expanding its therapeutic indication scope while maintaining kinase inhibition activity
2Reliability
If existing kinase inhibitors are developed, then cancer treatment approval is achieved, but autoimmune disease treatment approval is not achieved
Solution Approach 1:
The patent designs kinase inhibitors with broad-spectrum activity targeting multiple kinase families (KIT, CSF1R, PDGFR) to enable single compounds to treat multiple disease types including both cancer and autoimmune diseases, thereby expanding the versatility and indication scope of the therapeutic agents
Data Source
AI summary
The invention provides compounds of formula (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof,which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R and PDGFR (PDGFRα, PDGFRβ) kinases.